LONDON (Alliance News) - Summit Therapeutics PLC said Wednesday that Polar Capital LLP holds a 6.47% stake in the drug developer after a transaction on December 21.
Polar Capital's holding following the deal was 3.6 million direct shares plus American depository shares equivalent to another 1.8 million shares. Its holding prior to the transaction, if any, has not been disclosed.
Shares in Summit Therapeutics were up 11% at 21.70 pence on Wednesday.
